Inhalers often are covered by insurance, but the coverage can be so limited that it feels like they aren’t. High copays, formulary restrictions, prior authorization requirements, and step therapy protocols all create situations where your plan technically “covers” an inhaler but still leaves you paying $200 or more out of pocket. The reasons trace back to a tangle of patent strategies, rebate economics, and formulary decisions that have kept inhaler prices artificially high for decades.
How Patent Strategies Keep Prices High
Most inhaler active ingredients have been around for decades. Albuterol, for example, is an old drug. But inhalers aren’t simple pills. They’re drug-device combinations, and manufacturers have used the device side of that equation to extend patent protection far beyond what the drug alone would allow.
A study published in Chest found that for 39 brand-name inhalers, device patents extended market protection by a median of 5.5 years beyond the last drug-related patent. When manufacturers combine patent thickets with “product hopping,” switching from one delivery device to a newer one containing the same medication but protected by fresh patents, the median duration of patent protection stretches past 28 years. Seventy-seven percent of these device patents made no mention of active ingredients at all. They covered things like the canister mechanism or the mouthpiece design, features with no direct connection to the medication inside.
The practical result: generic alternatives that could drive down prices are blocked from the market for years longer than they should be. And without generic competition, insurers face a small number of expensive brand-name options to negotiate with.
The Propellant Switch That Reset the Clock
In the early 2000s, an international environmental treaty (the Montreal Protocol) phased out the chlorofluorocarbon propellants used in older inhalers. Manufacturers reformulated their products with a newer propellant called hydrofluoroalkane. The medications inside didn’t change, but the new delivery system allowed companies to file new patents and reset their exclusivity timelines. As the New England Journal of Medicine noted, these product hops to the new propellant cost payers and patients billions of dollars. Generic versions of the older CFC inhalers were pulled from the market, and patients were left with only the reformulated, patent-protected versions at much higher prices.
How Insurance Formularies Decide What You Pay
Your insurance plan doesn’t cover all inhalers equally. A committee reviews each drug for clinical effectiveness and cost, then places it on a tier. Lower tiers mean lower copays. Higher tiers, or outright exclusion from the formulary, mean you pay more or cover the full cost yourself. These decisions are supposed to be based on scientific evidence and safety, but they also factor in “pharmacoeconomic considerations,” which is where pricing and manufacturer rebates come into play.
Pharmacy benefit managers negotiate confidential rebates with drug companies. A manufacturer might offer a larger rebate to get its inhaler placed on a preferred tier, while a competitor’s similar product lands on a higher tier or gets excluded entirely. This means your doctor might prescribe the inhaler that works best for you, only for your insurance to push you toward a different one that the plan got a better deal on. The inhaler your doctor prescribed isn’t “not covered” in the traditional sense. It’s just been placed in a position where your out-of-pocket cost is punishingly high.
Step Therapy and Prior Authorization
Even when an inhaler is on your plan’s formulary, you may hit additional barriers. Step therapy, sometimes called “fail first,” requires you to try cheaper medications before your insurer will approve the one your doctor originally prescribed. This is common for respiratory conditions like asthma. You might need to use a lower-tier inhaler for weeks or months, and only after documenting that it didn’t adequately control your symptoms will the insurer approve the preferred option.
Prior authorization adds another layer. Your doctor has to submit paperwork justifying why you need a specific inhaler, often including details about medications you’ve already tried. This process can take days or longer, leaving you without medication in the meantime. Your doctor can sometimes speed things up by providing documentation that you’ve already failed on the step therapy alternatives, but it’s an added burden on both of you.
The Flovent Situation Explained
One high-profile example illustrates how rebate economics can backfire on patients. GlaxoSmithKline had raised the price of brand-name Flovent (fluticasone propionate) significantly over the years. Under Medicaid rules, manufacturers pay rebates when a drug’s price rises faster than inflation. The American Rescue Plan Act of 2021 eliminated the cap on those rebates starting in January 2024, which meant GSK would have owed rebates exceeding the drug’s actual price.
Rather than absorb that cost, GSK withdrew brand-name Flovent from the market in January 2024 and continued selling an identical product as an “authorized generic.” The medication was the same, but authorized generics are subject to lower rebate obligations. The problem: many families found that their insurance plan didn’t cover the authorized generic, or imposed high cost-sharing on it. Research published in the JAMA Network found that the withdrawal of brand-name Flovent was associated with increased discontinuation of inhaled steroid therapy among children, meaning some kids simply stopped using their asthma medication.
Recent Price Caps and State Laws
Political pressure has produced some relief. In 2024, both AstraZeneca and Boehringer Ingelheim announced $35 per month out-of-pocket caps on their inhaler products, effective June 1, 2024. These caps followed a Congressional investigation that found the four biggest inhaler manufacturers (AstraZeneca, Boehringer Ingelheim, GSK, and Teva) were charging between $200 and $600 per inhaler, typically purchased monthly. The $35 caps apply to eligible commercially insured patients, but eligibility varies and not all inhalers from all manufacturers are included.
Some states have gone further. New York signed legislation eliminating copays, coinsurance, and deductibles for asthma inhalers on state-regulated health insurance plans. The law requires every covered plan to include at least one rescue inhaler and one maintenance inhaler with zero cost-sharing. Other states have pursued similar measures, though coverage varies significantly depending on where you live and what type of plan you have.
What You Can Do About the Cost
If your inhaler costs more than you can afford, several options exist. Manufacturer patient assistance programs provide certain inhalers at no cost to people who are uninsured, underinsured, or meet specific income criteria. Teva, for example, runs a program that covers eligible patients for free. Organizations like Harbor Path deliver medications at no cost to uninsured patients in 24 states.
The Asthma and Allergy Foundation of America maintains a directory of assistance programs searchable by your insurance status, income, and specific medication. If your insurer has placed your prescribed inhaler on a high tier, your doctor can submit an appeal or exception request arguing medical necessity. This doesn’t always work, but it’s worth pursuing, especially if you’ve already tried and failed on the plan’s preferred alternatives.
Checking whether your plan offers a preferred alternative at a lower tier is the fastest route to savings. In many cases, a therapeutically similar inhaler on a lower tier will work just as well, and your doctor can make the switch without any gap in treatment.